Skip to main content

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Trial Status: Active

The purpose of this study is to investigate safety and anti-tumor activity of relatlimab combination therapy in solid cancers that are advanced or have spread

Inclusion Criteria

  • Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1
  • Available tumor tissue for biomarker analysis
  • Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1

Exclusion Criteria

  • Participants with known or suspected uncontrolled CNS metastases or with the CNS as the only site of active disease
  • Participants with a history of interstitial lung disease (ILD) / pneumonitis
  • Prior malignancy active within the previous 3 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer

California

Duarte
City of Hope Comprehensive Cancer Center
Status: ACTIVE

Colorado

Aurora
University of Colorado Hospital
Status: ACTIVE

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

  • Primary ID CA224-048
  • Secondary IDs NCI-2018-00575, 2018-000058-22
  • Clinicaltrials.gov ID NCT03459222